The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

This was the stock's second consecutive day of losses.

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

Discover why Vertex stock is undervalued with the potential of VX-548 as a groundbreaking pain treatment drug in the ...

Vertex Pharmaceuticals (VRTX ... we believe these estimate revisions are directly related to near-team stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.